{"id":"epalrestat","rwe":[{"pmid":"41830794","year":"2026","title":"Glycohypoxia: a hypothesis linking chronic hyperglycemia to functional hypoxia and diabetic complications in type 2 diabetes.","finding":"","journal":"Medical gas research","studyType":"Clinical Study"},{"pmid":"41774941","year":"2026","title":"Protection mechanism of epalrestat on glutamate-induced retinal excitotoxicity model based on network pharmacology.","finding":"","journal":"Biochemical and biophysical research communications","studyType":"Clinical Study"},{"pmid":"41592892","year":"2026","title":"Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity.","finding":"","journal":"Journal for immunotherapy of cancer","studyType":"Clinical Study"},{"pmid":"41564502","year":"2026","title":"Thiazolidinedione-based dual inhibitors of α-amylase and aldose reductase: Design, in vitro evaluation, and in vivo hypoglycemic activity.","finding":"","journal":"Bioorganic & medicinal chemistry","studyType":"Clinical Study"},{"pmid":"41550647","year":"2025","title":"Enhancing ferroptosis and inhibiting ABCB1 make the novel aldose reductase inhibitor 5F-E a promising sensitizer in liver cancer.","finding":"","journal":"Pharmaceutical science advances","studyType":"Clinical Study"}],"tags":[{"label":"epalrestat","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Aldose reductase","category":"target"},{"label":"AKR1B1","category":"gene"},{"label":"AKR1B10","category":"gene"},{"label":"CYP4A11","category":"gene"},{"label":"Active","category":"status"},{"label":"Diabetic neuropathy","category":"indication"},{"label":"Enzyme Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=EPALRESTAT","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:56:34.229604+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T00:56:48.162022+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:56:39.942776+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPALRESTAT","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:56:40.180110+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Aldose reductase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:41.198410+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL56337/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:56:40.866550+00:00"}},"allNames":"eabeth","offLabel":[],"synonyms":["ONO-2235","epalrestat","eabeth","sorbistat","kinedak"],"timeline":[{"date":"1992-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"aiSummary":"Epalrestat (Eabeth) is a marketed drug primarily indicated for diabetic neuropathy, with a key composition patent expiring in 2028. Its key strength lies in its specific mechanism of action targeting diabetic neuropathy, a condition with limited therapeutic options. The primary risk is competition from off-patent drugs like valproic acid, which has been available since 1978 and has 14 generics on the market.","approvals":[{"date":"1992-01-01","orphan":false,"company":"","regulator":"YEAR INTRODUCED"}],"brandName":"Eabeth","ecosystem":[{"indication":"Diabetic neuropathy","otherDrugs":[],"globalPrevalence":null}],"mechanism":{"target":"Aldose reductase","targets":[{"gene":"AKR1B1","source":"DrugCentral","target":"Aldose reductase","protein":"Aldose reductase"},{"gene":"AKR1B10","source":"DrugCentral","target":"Aldo-keto reductase family 1 member B10","protein":"Aldo-keto reductase family 1 member B10"},{"gene":"CYP4A11","source":"DrugCentral","target":"Cytochrome P450 4A11","protein":"Cytochrome P450 4A11"},{"gene":"AKR1A1","source":"DrugCentral","target":"Alcohol dehydrogenase [NADP(+)]","protein":"Alcohol dehydrogenase [NADP(+)]"},{"gene":"SORD","source":"DrugCentral","target":"Sorbitol dehydrogenase","protein":"Sorbitol dehydrogenase"}],"modality":"Small Molecule","drugClass":"epalrestat","explanation":"","oneSentence":"","technicalDetail":"Epalrestat inhibits the activity of aldose reductase, a key enzyme in the polyol pathway, which is involved in the reduction of glucose to sorbitol in nerve cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1021","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=EPALRESTAT","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EPALRESTAT","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:01:43.808126","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:56:48.162143+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"valproic acid","drugSlug":"valproic-acid","fdaApproval":"1978-02-28","genericCount":14,"patentStatus":"Off-patent — generic available","relationship":"same-target"}],"genericName":"epalrestat","indications":{"approved":[{"name":"Diabetic neuropathy","source":"DrugCentral","snomedId":230572002,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"valproic-acid","brandName":"valproic acid","genericName":"valproic acid","approvalYear":"1978","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT04925960","phase":"PHASE3","title":"Oral Epalrestat Therapy in Pediatric Subjects With PMM2-CDG","status":"TERMINATED","sponsor":"Maggie's Pearl, LLC","startDate":"2022-11-10","conditions":["Pmm2-CDG","Phosphomannomutase 2 Deficiency","Phosphomannomutase 2 Congenital Disorder of Glycosylation","Phosphomannomutase II Congenital Disorder of Glycosylation","Phosphomannomutase II Deficiency"],"enrollment":42,"completionDate":"2025-02-28"},{"nctId":"NCT06330233","phase":"NA","title":"Different Amounts of Moxibustion in the Treatment of DPN: A Clinical RCT Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Zhejiang Chinese Medical University","startDate":"2024-09-01","conditions":["Diabetic Peripheral Neuropathy","Pain","Moxibustion","Randomized Controlled Trial"],"enrollment":90,"completionDate":"2026-12-31"},{"nctId":"NCT06201611","phase":"PHASE2,PHASE3","title":"Evaluating a Nitric Oxide Generator, Nebivolol as a Disease Modifier in Patients With Diabetic Neuropathy.","status":"RECRUITING","sponsor":"St. John's Research Institute","startDate":"2024-11-15","conditions":["Diabetic Neuropathy Peripheral"],"enrollment":120,"completionDate":"2026-03-30"},{"nctId":"NCT05777226","phase":"PHASE2","title":"Research of SORD-CMT Natural History and Epalrestat Treatment","status":"NOT_YET_RECRUITING","sponsor":"The Third Xiangya Hospital of Central South University","startDate":"2023-04","conditions":["Charcot-Marie-Tooth Disease (CMT)"],"enrollment":30,"completionDate":"2026-04"},{"nctId":"NCT05184049","phase":"PHASE4","title":"Effects of Epalrestat on Peripheral Neuropathy and Central Nervous System in Diabetic Patients","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2022-01","conditions":["Diabetes"],"enrollment":72,"completionDate":"2023-10"},{"nctId":"NCT03244358","phase":"PHASE2","title":"Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer","status":"TERMINATED","sponsor":"Sun Yat-sen University","startDate":"2017-03-01","conditions":["Triple Negative Breast Cancer"],"enrollment":12,"completionDate":"2020-12-01"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"424DV0807X","CHEBI":"CHEBI:31539","INN_ID":"5896","UMLSCUI":"C0095278","chemblId":"CHEMBL56337","ChEMBL_ID":"CHEMBL56337","KEGG_DRUG":"D01688","DRUGBANK_ID":"DB15293","PDB_CHEM_ID":" EPR","PUBCHEM_CID":"1549120","IUPHAR_LIGAND_ID":"11371","MESH_SUPPLEMENTAL_RECORD_UI":"C038131"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":340,"therapeuticAreas":["Metabolic"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Mar 14","pmid":"41830794","title":"Glycohypoxia: a hypothesis linking chronic hyperglycemia to functional hypoxia and diabetic complications in type 2 diabetes.","journal":"Medical gas research"},{"date":"2026 Apr 23","pmid":"41774941","title":"Protection mechanism of epalrestat on glutamate-induced retinal excitotoxicity model based on network pharmacology.","journal":"Biochemical and biophysical research communications"},{"date":"2026 Jan 27","pmid":"41592892","title":"Targeting AKR1B1 reprograms tumor-associated macrophages to enhance antitumor immunity.","journal":"Journal for immunotherapy of cancer"},{"date":"2026 Apr","pmid":"41564502","title":"Thiazolidinedione-based dual inhibitors of α-amylase and aldose reductase: Design, in vitro evaluation, and in vivo hypoglycemic activity.","journal":"Bioorganic & medicinal chemistry"},{"date":"2025 Dec","pmid":"41550647","title":"Enhancing ferroptosis and inhibiting ABCB1 make the novel aldose reductase inhibitor 5F-E a promising sensitizer in liver cancer.","journal":"Pharmaceutical science advances"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"1992","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"OTHER","regulator":"YEAR INTRODUCED","status":"approved","approval_date":"1992-01-01T00:00:00.000Z","mah":"","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":2,"withResults":0},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T00:56:48.162143+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}